Prognostic Value of the MAGNIMS Score and its Application in Clinical Outcome Assessment of Disease Modifying Therapy in Patients with Relapsing Multiple Sclerosis: Results from the OPTIMUM Study of Ponesimod

被引：0
|
作者：
Keenan, A. [1 ]
Gandhi, K. [1 ]
Le, H. H. [1 ]
Turkoz, I. [1 ]
Guo, S. [2 ]
Liao, W.
Pelligra, C. G. [3 ]
机构：
[1] Janssen Pharmaceut, Titusville, NJ USA
[2] Evidera, Waltham, MA USA
[3] Evidera, Bogota, Colombia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P085
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [31] Safety of Using Disease-Modifying Therapy Post-Alemtuzumab Treatment in Patients with Active Relapsing-Remitting Multiple Sclerosis in the Alemtuzumab Clinical Development Program
    Bass, Ann
    Edwards, Keith
    Khatri, Bhupendra
    Selmaj, Krzysztof
    Margolin, David
    Kasten, Linda
    Sorensen, Per
    NEUROLOGY, 2016, 86
  • [32] Epidemiological study to evaluate the course of disease and therapy decisions in relapsing-remitting multiple sclerosis patients with long-term first-line disease modifying treatment
    Schmidt, S.
    Koehler, J.
    Winterstein, C.
    Schicklmaier, P.
    Wernsdoerfer, C.
    Kallmann, B.
    EUROPEAN JOURNAL OF NEUROLOGY, 2015, 22 : 448 - 448
  • [33] Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis A Randomized Clinical Trial
    Burt, Richard K.
    Balabanov, Roumen
    Burman, Joachim
    Sharrack, Basil
    Snowden, John A.
    Oliveira, Maria Carolina
    Fagius, Jan
    Rose, John
    Nelson, Flavia
    Barreira, Amilton Antunes
    Carlson, Kristina
    Han, Xiaoqiang
    Moraes, Daniela
    Morgan, Amy
    Quigley, Kathleen
    Yaung, Kimberly
    Buckley, Regan
    Alldredge, Carri
    Clendenan, Allison
    Calvario, Michelle A.
    Henry, Jacquelyn
    Jovanovic, Borko
    Helenowski, Irene B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (02): : 165 - 174
  • [34] The Global Adherence Project - A multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis
    Devonshire, V.
    Lapierre, Y.
    MacDonell, R.
    Ranto Tello, C.
    Patti, F.
    Fontoura, P.
    Suchet, L.
    Hyde, R.
    Balla, I.
    Kieseier, B.
    Frohman, E.
    MULTIPLE SCLEROSIS, 2006, 12 : S82 - S82
  • [35] Motor conduction, walking ability and cognitive function in patients with clinical isolated syndromes and remitting relapsing multiple sclerosis: a one year follow-up study after initiation of a disease modifying therapy
    Hofstadt-van Oy, U.
    Keune, P.
    Menge, U.
    Oschmann, P.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 244 - 244
  • [36] Reducing return of disease activity in patients with relapsing multiple sclerosis transitioned from natalizumab to teriflunomide: 12-month interim results of teriflunomide therapy
    Cohan, Stanley L.
    Edwards, Keith
    Lucas, Lindsay
    Gervasi-Follmar, Tiffany
    O'Connor, Judy
    Siuta, Jessica
    Kamath, Vineetha
    Garten, Lore
    Chen, Chiayi
    Thomas, James
    Smoot, Kyle
    Kresa-Reahl, Kiren
    Spinelli, Kateri J.
    MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2019, 5 (01)
  • [37] Time to Qualifying Relapse by Previous Disease Modifying Therapy Status in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets over 2 Years in the CLARIFY-MS Study
    Patti, Francesco
    Brochet, Bruno
    Havrdova, Eva Kubala
    Solari, Alessandra
    Hupperts, R. M. M.
    Langdon, Dawn
    Lechner-Scott, Jeannette
    Piehl, Fredrik
    Selmaj, Krzysztof
    Smyk, Andrzej
    Lehn, Annette
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 747 - 748
  • [38] Alemtuzumab Safety, Efficacy, and Tolerability in Paediatric Patients with Active Relapsing-Remitting Multiple Sclerosis Despite Prior Treatment with Disease-Modifying Therapy: LemKids Study Design
    Chitnis, T.
    Banwell, B.
    Arnold, D.
    Arque, M. -J.
    Chirieac, M.
    Rakhade, S.
    Jacobs, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 130 - 130
  • [39] Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression in Relapsing-Remitting Multiple Sclerosis: Results from a 48-Month Extension Study
    Rinaldi, Francesca
    Perini, Paola
    Atzori, Matteo
    Favaretto, Alice
    Seppi, Dario
    Gallo, Paolo
    MULTIPLE SCLEROSIS INTERNATIONAL, 2015, 2015
  • [40] Relationship between early disease activity and long-term clinical outcome: results from the phase 3 TRANSFORMS study extension at 4.5 years in relapsing-remitting multiple sclerosis
    Hartung, H-P
    Barkhof, F.
    Comi, G.
    Kappos, L.
    Khatri, B.
    Montalban, X.
    Pelletier, J.
    Kornyeyeva, E.
    Meier, D. Piani
    Ritter, S.
    von Rosenstiel, P.
    Tomic, D.
    Cohen, J.
    JOURNAL OF NEUROLOGY, 2013, 260 : S71 - S71
12345